HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

De novo tumors after liver transplantation: a single-institution experience.

Abstract
The aims of this analysis are to characterize the incidence and types of malignancies and tumor-specific mortality in our institution. Retransplantation, rejection episodes, and OKT3 use were evaluated. Our single-institution prospective database of 1,570 liver transplantations in 1,421 patients was analyzed. Data were statistically analyzed regarding sex, age at transplantation, time from transplantation to diagnosis of tumor, tumor type, and follow-up time. One hundred twenty-five patients (8.8%) developed de novo tumors; 69 patients were men, 56 patients were women. Seventeen patients received more than one allograft. De novo tumors were as follows: skin, 41; lymphomas, 35; lung, 11; colon, 6; anal, 2; rectal, 1; breast, 7; thyroid, 3; oropharyngeal squamous cell, 3; metastatic without primary tumor identified, 4; renal cell, 3; Kaposi's sarcoma, 1; angiosarcoma, 1; uterine, 1; ovarian, 1; pituitary, 1; pancreatic, 2; cholangiocarcinoma, 1; and esophageal, 1. These tumors developed in a statistically significant chronological sequence. Lung cancers and lymphomas showed shorter mean survival times, as well as greater mortality. OKT3 use and rejection did not show significance in tumor development. De novo tumors post-liver transplantation affected our population in a distribution similar to that of the general non-transplantation population. Intense short courses of immunosuppression for rejection were not as important as chronic immunosuppression in the development of tumors. The risk for development was not enough to preclude transplantation. We found that tumors developed in chronological fashion. Therefore, directed surveillance, patient education, and early detection may facilitate earlier treatment.
AuthorsEdmund Q Sanchez, Shigeru Marubashi, Ghapjoong Jung, Marlon F Levy, Robert M Goldstein, Ernesto P Molmenti, Carlos G Fasola, Thomas A Gonwa, Linda W Jennings, Barbara K Brooks, Goran B Klintmalm
JournalLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (Liver Transpl) Vol. 8 Issue 3 Pg. 285-91 (Mar 2002) ISSN: 1527-6465 [Print] United States
PMID11910575 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Muromonab-CD3
Topics
  • Adult
  • Female
  • Graft Rejection (complications)
  • Humans
  • Immunosuppressive Agents (adverse effects)
  • Incidence
  • Liver Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Muromonab-CD3 (adverse effects)
  • Neoplasms (chemically induced, epidemiology, etiology, mortality)
  • Reoperation
  • Retrospective Studies
  • Survival Analysis
  • Time Factors
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: